Skip to main content
Premium Trial:

Request an Annual Quote

Dante Genomics to Offer SomaLogic Proteomics Testing to Researchers in Europe

NEW YORK – SomaLogic and Italy's Dante Genomics said on Monday that they have partnered to offer services on SomaLogic's SomaScan proteomics platform to researchers in Europe.

Under the terms of the partnership, Dante will run SomaScan, which can measure approximately 7,000 proteins in plasma or serum samples, out of its laboratory in Italy. It will be the first SomaLogic authorized service site in that country, offering services to the rest of Europe.

"By combining proteomics and genomics, we will develop clinical insights and actionable results," said Andrea Riposati, CEO and cofounder of Dante Genomics, in a statement. "We are excited for the future of multiomics, where partnerships like this will mean overall better healthcare for more people around the world."

In 2022, Dante Labs, the firm's clinical testing business, partnered with the Italian government to introduce clinical whole-genome sequencing to the country's healthcare system.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.